Sign Up Today and Learn More About Eaze Stock
Invest in or calculate the value of your shares in Eaze or other pre-IPO companies through EquityZen's platform.
About Eaze Stock
Founded
2014
Headquarters
San Francisco, CA, US
Total Funding
156M
Industries
Messaging and Telecommunications, Sports, Content and Publishing
Eaze is an app-based medical marijuana marketplace that connects verified patients to nearby dispensaries for on-demand delivery. For those without a Medical Marijuana license, Eaze provides their app Eaze MD which offers live video-call consultations with on-demand doctors. Eaze differentiates their services from other medicinal marijuana services by optimizing their delivery algorithm which allows most deliveries to occur between 10-20 minutes.Â
Source: Eaze
Eaze Press Mentions
Stay in the know about the latest news on Eaze
Glass House Brands and Eaze Partner to Launch PLUS Cannabis Gummies in Florida
globenewswire • Apr 10, 2025
California workers for marijuana operator Eaze secure 3-year bargaining pact
mjbizdaily • Feb 24, 2025
Eaze secures $10M to resurrect cannabis operations after foreclosure drama
greenmarketreport • Feb 07, 2025
Cannabis cultivator Eaze to expand Florida operations after near-shutdown, plans new stores
bizjournals • Jan 23, 2025
Reborn Eaze plants first cannabis crop at newly expanded Florida cultivation facility
mjbizdaily • Jan 16, 2025
Investors in Eaze
Discover investors in Eaze stock and explore their portfolio companies
Eaze Management
Leadership team at Eaze
Founder
Keith McCarty
CEO
Jim Patterson
Join now and verify your accreditation status to gain access to:
- Eaze Current Valuation
- Eaze Stock Price
- Eaze Management
- Available deals in Eaze and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Eaze Cap Table and Funding History by Share Class and Liquidity Preferences
- Eaze Revenue and Financials
- Eaze Highlights
- Eaze Business Model
- Eaze Risk Factors
- Eaze Research Report from SACRA Research
Trading Eaze Stock
How to invest in Eaze stock?
Accredited investors can buy pre-IPO stock in companies like Eaze through EquityZen funds. These investments are made available by existing Eaze shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Eaze stock?
Shareholders can sell their Eaze stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
